Bone mineral density in children with beta-thalassemia major in Diyarbakir

Bone

Volumn 49, Issue 4, 2011, Pages 819-823

  Pirinççioglu, Ayfer Gözü ^a   Akpolat, Veysi ^a   Köksal, Orhan ^a   Haspolat, Kenan ^a   Söker, Murat ^a  

^a DICLE UNIVERSITY   (Turkey)

Author keywords

Beta thalassemia; Bone mineral density; Children; Osteopenia; Osteoporosis

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; COLLAGEN TYPE 1; CREATININE; DEFEROXAMINE; FERRITIN; OSTEOCALCIN; PARATHYROID HORMONE; PHOSPHORUS;

ADOLESCENT; AGE; ANTHROPOMETRY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BETA THALASSEMIA; BLOOD TRANSFUSION; BONE DENSITY; CHILD; CLINICAL ARTICLE; COLORIMETRY; CONTROLLED STUDY; CREATININE URINE LEVEL; FEMALE; GENDER; HEIGHT; HUMAN; MALE; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PRESCHOOL CHILD; PROTEIN BLOOD LEVEL; SCHOOL CHILD; SOCIOECONOMICS; TREATMENT RESPONSE; TURKEY (REPUBLIC); WEIGHT;

ABSORPTIOMETRY, PHOTON; ADOLESCENT; ANTHROPOMETRY; BETA-THALASSEMIA; BONE DENSITY; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; DEFEROXAMINE; FEMALE; FEMUR; HUMANS; INFANT; LUMBAR VERTEBRAE; MALE; PARATHYROID HORMONE; TURKEY; VITAMIN D;

EID: 80052296789     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2011.07.014     Document Type: Article

References (37)

1. Voskaridou E., Terpos E., Spina G., Palermos J., Rahemtulla A., Loutradi A., Loukopoulos D. Pamidronate is an effective treatment for osteoporosis in patients with beta thalassemia. Br J Haematol 2003, 123:730-737.
2. Pollak R.D., Rachmilewita E., Blumenfeld A., Idelson M., Goldfarb A.W. Bone mineral metabolism in adults with beta-thalassaemia major and intermedia. Br J Haematol 2000, 111:902-907.
3. Garofalo F. Bone mass and metabolism in thalassemic children and adolescents treated with different iron-chelating drugs. J Bone Miner Res 2004, 22:52-57.
4. Heaney R.P. Nutritional factors in osteoporosis. Annu Rev Nutr 1993, 13:287-316.
5. Jensen C.E. High incidence of osteoporosis in thalassaemia major. J Pediatr Endocrinol Metab 1998, 11(SUPPL. 3):975-977.
6. Yilmaz N., Bayram M., Erbagci A.B., Kilincer M.S. Diagnostic value of biochemical markers of bone turnover and postmenopausal osteoporosis. Clin Chem Lab Med 1999, 37(2):137-143.
7. Morabito N., Lasco A., Gaudio A., Crisafulli A., Di Pietro C., Meo A., Frisina N. Bisphosphonates in the treatment of thalassemia-induced osteoporosis. Osteoporos Int 2002, 13:644-649.
8. Molyvda-Athanasopoulou E., Sioundas A., Karatzas N., Aggellaki M., Pazaitou K., Vainas I. Bone mineral density of patients with thalassemia major: Four year follow-up. Calcif Tissue Int 1999, 64:481-484.
9. Pirinccioglu A.G., Deniz T., Gokalp D., Beyazit N., Haspolat K., Soker M. Assessment of Thyroid function in children aged 1-13 years with beta-thalassemia major. Iran J Pediatr 2011, 21:77-82.
10. Voskaridou E., Terpos E. New insights into the pathophysiology and management of osteoporosis in patients with beta thalassaemia. Br J Haematol 2004, 127:127-139.
11. Jensen C.E., Tuck S.M., Agnew J.E., Koneru S., Morris R.W., Yardumian A., Prescott E., Hoffbrand A.V., Wonke B. High prevalence of low bone mass in thalassaemia major. Br J Haematol 1998, 103:911-915.
12. Vogiatzi M.G., Autio K.A., Schneider R., Giardina P.J. Low bone mass in prepubertal children with thalassemia major: insights into the pathogenesis of low bone mass in thalassemia. J Pediatr Endocrinol Metab 2004, 17:1415-1421.
13. Christoforidis A., Perifanis V., Papadopoulou E., Dimitriadou M., Kazantzidou E., Vlachaki E., Tsatra I. Poor correlations between measurements of bone quality by quantitative ultrasound sonography and dual energy X-ray absorptiometry in patients with b-thalassaemia major. Eur J Haematol 2008, 82:15-21.
14. Mahachoklertwattana P., Chuansumrit A., Sirisriro R., Choubtum L., Sriphrapradang A., Rajatanavin R. Bone mineral density, biochemical and hormonal profiles in suboptimally treated children and adolescents with betathalassaemia disease. Clin Endocrinol (Oxf) 2003, 58:273-279.
15. Lasco A., Morabito N., Gaudio A., Crisafulli A., Meo A., Denuzzo G., Frisina N. Osteoporosis and beta-thalassemia major: role of the IGF-I/IGFBP-III axis. J Endocrinol Invest 2002, 25:338-344.
16. Rubin K., Schirduan V., Gendreau P., Sarfarazi M., Mendola R., Dalsky G. Predictors of axial and peripheral bone mineral density in healthy children and adolescents, with special attention to the role of puberty. J Pediatr 1993, 123:863-870.
17. Mahachoklertwattana P., Chuansumrit A., Choubtum L., Sriphrapradang A., Sirisriro R., Rajatanavin R. J Pediatr Endocrinol Metab 2002, 15:1531-1535.
18. Di Stefano M., Chiabotto P., Roggia C., Garofalo F., Lala R., Piga A., Isaia G.C. Bone mass and metabolism in thalassemic children and adolescents treated with different iron-chelating drugs. J Bone Miner Metab 2004, 22:53-57.
19. Eren E., Yilmaz N. Biochemical markers of bone turnover and bone mineral density in patients with b-thalassemia major. Int J Clin Pract 2005, 59(1):46-51.
20. Moulas A., Challa A., Chaliasos N., Lapatsanis P.D. VitaminD metabolites (25-hydroxyvitamin D, 24,25-dihydroxyvitamin D and 1,25-dihydroxyvitamin D) and osteocalcin in b-thalassemia. Acta Paediatr 1997, 86:594-599.
21. Bielinski B.K., Darbyshire P.J., Mathers L., Crabtree N.J., Kirk J.M., Stirling H.F., Shaw N.J. Impact of disordered puberty on bone density in b-thalassemia major. Br J Haematol 2003, 120:353-358.
22. Soliman A.T., Banna E.I., Abdel Fattah M. Bone mineral density in prepubertal children with beta-thalassemia: correlation with growth and hormonal data. Metabolism 1998, 47:541-548.
23. Salama O.S., Al-Tonbary Y.A., Shahin R.R., Eldeen O.A. Unbalanced bone turnover in children with beta-thalassemia. Hematology 2006, 11(3):197-202.
24. Jensen C.E., Tuck S.M., Old J., Morris R.W., Yardumian A., De Sanctis V., Hoffbrand A.V., Wonke B. Incidence of endocrine complications and clinical disease severity related to genotype analysis and iron overload in patients with b-thalassemia. Eur J Haematol 1997, 9:76-81.
25. Portale A.A., Halloran B.P., Murphy M.M., Morris R.C. Oral intake of phosphorus can determine the serum concentration of 1,25-hydroxyvitamin D by determining its production rate in humans. J Clin Invest 1986, 77:7-12.
26. Yamamoto M., Igarashi T., Muramatsu M., Fukagawa M., Motokura T., Ogata E. Hypocalcemia increases and hypercalcemia decreases the steady-state level of parathyroid hormone messenger RNA in the rat. J Clin Invest 1989, 83:1053-1056.
27. Trechsel U., Eisman J.A., Fischer J.A., Bonjour J.P., Fleisch H. Calcium dependent parathyroid hormone-independent regulation of 1,25-hydroxyvitamin D. Am J Physiol 1980, 239:E119-E124.
28. Domrongkitchaiporn S., Sirikulchayanonta V., Angchagsuksiri P., Stitchantrakul W., Kanokkantapong C., Rajatanavin R. Abnormalities in bone mineral density and bone histology in thalassemia. J Bone Miner Res 2003, 18:1682-1688.
29. Chow L.H., Frei J.V., Hodman A.B., Valberg L.S. Low serum 25 hydroxyvitamin D in hereditary hemochromatosis: relation to iron status. Gastroenterology 1985, 88:865-869.
30. Yazigi A., Maalouf G., Inati-Khoriati A., Tamim H., Saab C. Bone mineral density in β--thalassemic Lebanese children. J Musculoskel Neuron Interact 2002, 2(5):463-468.
31. Toumba M., Skordis N. Osteoporosis syndrome in thalassaemia major: an overview. J Osteoporos 2010, 2010:1-7. 10.4061/2010/537673.
32. Sartorio A., Conte G., Conti A., Masala A., Alagna S., Rovasio P., Faglia G. Effects of 12months rec-GH therapy on bone and collagen turnover and bone mineral density in GH deficient children with thalassemia major. J Endocrinol Invest 2000, 23:356-361.
33. Fung Ellen B., Vichinsky Elliott P., Kwiatkowski Janet L., Huang James, Bachrach Laura K., Sawyer Aenor J., Zemel Babette S. Characterization of low bone mass in young patients with thalassemia by DXA, pQCT and markers of bone turnover. Bone 2011, 48:1305-1312.
34. Gratwick G.M., Bullough P.G., Bohne W.H., Markenson A.L., Peterson C.M. Thalassaemic osteoarthropathy. Ann Intern Med 1978, 88:494-501.
35. Johanson N.A. Musculoskeletal problems in hemoglobinopathy. Orthop Clin North Am 1990, 21:191-198.
36. Naves-Diaz M.L., Elorriaga R., Canteros A., Cannata Andia J.B. Effect of desferrioxamine and deferiprone (L1) on the proliferation of MG-63 bone cells and phosphatase alkaline activity. Nephrol Dial Transplant 1998, 13:23-28.
37. Wonke B. Bone disease in beta-thalassaemia major. Br J Haematol 1998, 103:897-901.